Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Morning Review
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
    • Insider Transactions
  • inderesTV
  • Portfolio
  • Forum
  • Premium
  • Femme
  • Learn
    • Investing School
    • Q&A
    • Analysis School
  • About Us
    • Our Coverage
    • Team
Press release

BioStock: Stayble Therapeutics presents phase IIb data within one month

Stayble Therapeutics

Stayble Therapeutics is facing the company's most important milestone to date, presenting top-line data from the phase IIb study with STA363 in patients with degenerative disc disease. The results from the phase IIb study are expected to be presented in November or at the latest in early December. Subject to positive results, the company plans to intensify partnering activities in collaboration with the transaction advisor Ferghana Partners. 

Read the full article at biostock.se:

https://www.biostock.se/en/2023/11/stayble-therapeutics-presents-phase-iib-data-within-one-month/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se

Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Get in touch
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.